Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
- Conditions
- GlioblastomaSquamous Cell CarcinomaHodgkin LymphomaNon-hodgkin LymphomaBreast CancerProstate CancerGastric CancerOvarian CancerAcute LeukemiaPancreatic Cancer
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- AVM Biotechnology Inc
- Registration Number
- NCT05974410
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
Phase 1
Not yet recruiting
- Conditions
- ARDSCovid19Influenza, Human
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- AVM Biotechnology Inc
- Target Recruit Count
- 16
- Registration Number
- NCT04366115
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- AVM Biotechnology Inc
- Target Recruit Count
- 144
- Registration Number
- NCT04329728
- Locations
- 🇺🇸
UCLA Medical Center of Hematology/Oncology, Los Angeles, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
© Copyright 2025. All Rights Reserved by MedPath